Advocacy intelligence hub — real-time data for patient organizations
Sogroya: FDA approved
Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Sogroya
(somapacitan-beco)Orphan drugNovo Nordisk Pharmaceuticals
12.1 Mechanism of Action Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells resulting in intracellular signal transd...